Nov 1, 2023
MediSieve CEO, George Frodsham, Celebrated as an 'Engineering Icon' in the Royal Academy of Engineering and TfL Campaign
The campaign features a unique Tube map naming stations after prominent engineers, in celebration of the National Engineering Day.
LONDON, November 1, 2023 – MediSieve announced that its CEO, Dr George Frodsham, has been recognised as an 'Engineering Icon' in a unique campaign launched by the Royal Academy of Engineering in partnership with Transport for London (TfL). This innovative campaign, released in celebration of National Engineering Day on November 1st, features a specially designed Tube map where each station is named after a leading engineer, both past and present.
The 'Engineering Icons' Tube map is a creative initiative that aims to highlight the significant contributions of engineers to society. George Frodsham's inclusion in this campaign is a testament to his pioneering work and impact in the field of engineering. The map is available for viewing on the TfL website and at the London Transport Museum, offering a unique insight into the world of engineering and its many distinguished professionals.
"I am immensely proud to be recognised alongside some of the most influential figures in engineering history," stated Dr Frodsham. "This campaign by the Royal Academy of Engineering and TfL not only celebrates the exceptional talents and achievements of engineers but also serves as an inspiration for future generations."
The collaboration between the Royal Academy of Engineering and TfL in creating this map is a significant step in raising public awareness about the importance of engineering and its role in shaping our daily lives. The campaign coinciding with National Engineering Day provides an excellent opportunity to reflect on the transformative impact of engineering on society.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Capture System captures all the Magnetic Beads and bound targets, preventing their return to the patient.
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
INVESTOR AND PARTNERSHIP CONTACT: